Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04872738 · ClinicalTrials.gov registry record
Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 714
- Enrollment target
NCT04872738: Completed study, sponsored by Massachusetts General Hospital.
NCT04872738 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 714 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04872738 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 714 participants
- Enrollment target
Study Summary
This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery. Lymph node swelling is a known and common side effect of both the Moderna and Pfizer COVID-19 vaccines. This is the body's normal reaction to the vaccine. It is worrisome that lymph node swelling after the vaccine mimics that found in breast cancer which has spread to the lymph nodes. This side effect will cause worry and anxiety amongst patients as a result. For patients who have had lymph node removal (axillary lymph node dissection or sentinel lymph node biopsy) and are at risk of lymphedema, the investigators are concerned that the lymph node swelling may tax the lymphatic system and incite lymphedema in those at risk or worsen it in those with BCRL. Fear of lymphedema is high in this population and the investigators need to better understand what risk, if any, lymph node swelling after the COVID-19 vaccine imparts to BCRL risk.
Interventions
- OTHER Survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2023-03-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04872738
The ClinicalTrials.gov registry entry for NCT04872738 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Survey is the first listed.
NCT04872738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04872738 about?
NCT04872738 is a clinical study titled "Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment". This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery. Lymph node swelling is a known and common side effect of both the Moderna and Pfizer COVID-19 vaccines. This is the body's normal reaction to the vaccine. It is ...
What is the current status of trial NCT04872738?
This trial is currently completed. The enrollment target is 714 participants. The study started on 2021-05-07. Estimated completion is 2023-03-17.
What interventions are being tested in trial NCT04872738?
The interventions under investigation include: Survey (OTHER).
Who is sponsoring clinical trial NCT04872738?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.